Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalOncologyBreast CancerTrial Update

Study on Gut Microbiota and Cachexia in Breast Cancer Patients Under Home Care

This study could redefine treatment strategies for cachexia in breast cancer patients, particularly through the use of probiotics. Successful outcomes may lead to new clinical practices and product developments, impacting patient care in oncology.

Published: June 21, 2026
Updated: June 21, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Breast Cancer
Asset: Study
Indication: breast cancer treatment protocols
Trial SummaryCLN

Phase III

breast cancer treatment protocols

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

This study could redefine treatment strategies for cachexia in breast cancer patients, particularly through the use of probiotics. Successful outcomes may lead to new clinical practices and product developments, impacting patient care in oncology.

Why it matters

This study could redefine treatment strategies for cachexia in breast cancer patients, particularly through the use of probiotics. Successful outcomes may lead to new clinical practices and product developments, impacting patient care in oncology.

What changed

Trial Update

Analysis

A study is evaluating the association between cancer cachexia and gut microbiota in breast cancer patients receiving home care, including the impact of a probiotic mixture.

This study could redefine treatment strategies for cachexia in breast cancer patients, particularly through the use of probiotics. Successful outcomes may lead to new clinical practices and product developments, impacting patient care in oncology.

Monitor results from the trial, particularly the efficacy of the probiotic mixture compared to placebo and any changes in cachexia-related measures.

Related companies & assets

Assets

  • Study →
  • probiotic product developers →

Sources & Humanexa intelligence

Source links

  • Study on Gut Microbiota and Cachexia in Breast Cancer Patients Under Home Care ↗

Related Humanexa pages

  • Study on Gut Microbiota and Cachexia in Breast Cancer Patients Under Home Care →

Related signals

Trial SummaryCLN

Phase III

Gastroenterology / Ulcerative Colitis

Status

Active

Sponsor

Eli Lilly

Signal Score

8.2

Clinicalhigh signal

Eli Lilly's LY4268989 Study with Mirikizumab in Ulcerative Colitis Underway

A clinical trial is evaluating the safety and effectiveness of LY4268989 co-administered with mirikizumab in adults with moderately to severely active ulcerative colitis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

Neurology / Multiple System Atrophy

Status

Active

Sponsor

Teva

Signal Score

8.2

Clinicalhigh signal

Teva's TEV-56286 Trial for Multiple System Atrophy Underway

Teva is conducting a trial to evaluate the efficacy and safety of TEV-56286 in adults with Multiple System Atrophy.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.